...
首页> 外文期刊>Journal of Clinical Microbiology >Use of Recombinant Antigens for Sensitive Serodiagnosis of American Tegumentary Leishmaniasis Caused by Different Leishmania Species
【24h】

Use of Recombinant Antigens for Sensitive Serodiagnosis of American Tegumentary Leishmaniasis Caused by Different Leishmania Species

机译:重组抗原在由不同利什曼原虫引起的美国皮肤性利什曼病敏感血清学诊断中的应用

获取原文
           

摘要

American tegumentary leishmaniasis (ATL) (also known as cutaneous leishmaniasis [CL]) is caused by various species of protozoa of the genus Leishmania. The diagnosis is achieved on a clinical, epidemiological, and pathological basis, supported by positive parasitological exams and demonstration of leishmanin delayed-type hypersensitivity. Serological assays are not routinely used in the diagnosis because many are considered to have low sensitivity and the particular Leishmania species causing the disease can lead to variable performance. In the present study, we generated recombinant versions of two highly conserved Leishmania proteins, Leishmania (Viannia) braziliensis-derived Lb8E and Lb6H, and evaluated both in enzyme-linked immunosorbent assays (ELISA). Recombinant Lb6H (rLb6H) had better performance and reacted with 100.0% of the ATL and 89.4% of the VL samples. These reactions with rLb6H were highly specific (98.5%) when compared against those for samples from healthy control individuals. We then assessed rLb6H against sera from ATL patients infected with different species of Leishmania prevalent in Brazil [Leishmania (Leishmania) amazonensis, L. (Viannia) braziliensis, and L. (V.) guyanensis] and samples from patients with other infectious diseases. In analyses of 500 sera, ELISA using rLb6H detected all 219 ATL samples (sensitivity of 100.0%) with an overall specificity of 93.9% (considering healthy individuals and other infectious diseases patients). Only a minority of samples from Chagas disease patients possessed antibodies against rLb6H, and all of these responses were low (with a highest reactivity index of 2.2). Taken together, our data support further evaluation of rLb6H and the potential for its routine use in the serological diagnosis of ATL.
机译:美国四肢利什曼病(ATL)(也称为皮肤利什曼病[CL])是由利什曼原虫属的各种原生动物引起的。该诊断是在临床,流行病学和病理学基础上进行的,并得到了积极的寄生虫学检查和利什曼宁迟发型超敏反应的证明。血清学检测通常不用于诊断,因为许多检测灵敏度低,并且引起疾病的特定利什曼原虫种类可能导致性能变化。在本研究中,我们生成了两个高度保守的利什曼原虫蛋白(利什曼原虫(Viannia)来自巴西的利什曼原虫)衍生的Lb8E和Lb6H的重组版本,并在酶联免疫吸附测定(ELISA)中进行了评估。重组Lb6H(rLb6H)具有更好的性能,并与100.0%的ATL和89.4%的VL反应。与来自健康对照个体的样品相比,这些与rLb6H的反应具有很高的特异性(98.5%)。然后,我们针对来自感染了巴西[Leishmania(Leishmania)amazonensis, L )的不同种类利什曼原虫的ATL患者的血清评估了rLb6H的抗血清。 (Viannia)braziliensis和 L 。 ( V 。)Guyanensis]和其他传染病患者的样本。在对500个血清的分析中,使用rLb6H的ELISA检测到所有219个ATL样品(灵敏度为100.0%),总特异性为93.9%(考虑到健康个体和其他传染病患者)。恰加斯(Chagas)病患者中只有少数样品具有针对rLb6H的抗体,并且所有这些响应都很低(最高反应指数为2.2)。综上所述,我们的数据支持进一步评估rLb6H及其在ATL血清学诊断中常规使用的潜力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号